Post-Graduate Institute, Heilongjiang University of Chinese Medicine, Harbin 150040, Heilongjiang, China.
Institute of Pharmaceutical & Food Engineering, Shanxi University of Chinese Medicine, Jinzhong 030619, Shanxi, China.
Comput Math Methods Med. 2022 Oct 11;2022:2287470. doi: 10.1155/2022/2287470. eCollection 2022.
To systematically evaluate the clinical efficacy of modified Xiebai Powder or modified Xiebai Powder combined with Western medicine in the treatment of pneumonia and explore its potential mechanism of action.
Meta-analysis was used to screen the eligible literature on randomized controlled trials (RCTs) about Xiebai Powder in the treatment of pneumonia, and Review Manager 5.3 software was used for statistical analysis of the data. Based on the results of the meta-analysis, the active ingredients in Xiebai Powder and their therapeutic targets, disease-related targets, and intersection targets were screened using methods of network pharmacology, and their biological processes and key signaling pathways were analyzed using bioinformatics tools. Molecular docking was carried out to verify and predict the mechanisms for Xiebai Powder combined with Western medicine in the treatment of pneumonia.
A total of 16 papers were screened out, with a total of 1,465 patients. The results of the meta-analysis showed that modified Xiebai Powder or modified Xiebai Powder combined with Western medicine were superior to conventional Western medicine in terms of clinical efficacy, shortening the disappearance time of symptoms (body temperature, cough, and pulmonary rales) and reducing the level of C-reactive protein, and the incidence of adverse reactions was significantly reduced. A total of 40 active ingredients in Xiebai Powder and 285 therapeutic targets of Xiebai Powder combined with azithromycin after deduplication were screened out from the database. KEGG enrichment analysis showed that Xiebai Powder combined with azithromycin might play a role in the treatment of pneumonia through the IL-17 signaling pathway, tumor necrosis factor signaling pathway, C-type lectin receptor signaling pathway, Toll-like receptor signaling pathway, and HIF-1 signaling pathway.
Modified Xiebai Powder or modified Xiebai Powder combined with azithromycin has better effects in treating pneumonia, and modified Xiebai Powder combined with azithromycin may play a role in treating pneumonia through several pathways such as the IL-17 signaling pathway.
系统评价加味泻白散或加味泻白散联合西药治疗肺炎的临床疗效，并探讨其作用机制。
采用 Meta 分析方法，对加味泻白散治疗肺炎的随机对照试验（RCT）进行文献筛选，采用 Review Manager 5.3 软件对数据进行统计学分析。基于 Meta 分析结果，采用网络药理学方法筛选加味泻白散的活性成分及其治疗靶点、疾病相关靶点和交集靶点，并利用生物信息学工具分析其生物学过程和关键信号通路，采用分子对接验证并预测加味泻白散联合西药治疗肺炎的作用机制。
共筛选出 16 篇文献，纳入患者共 1465 例。Meta 分析结果显示，加味泻白散或加味泻白散联合西药在临床疗效、症状（体温、咳嗽、肺部啰音）消失时间及 C 反应蛋白水平降低方面均优于常规西药，且不良反应发生率明显降低。从数据库中筛选出加味泻白散的 40 个活性成分和泻白散联合阿奇霉素的 285 个治疗靶点，经去重后共 279 个治疗靶点。KEGG 富集分析显示，泻白散联合阿奇霉素可能通过白细胞介素-17（IL-17）信号通路、肿瘤坏死因子（TNF）信号通路、C 型凝集素受体（CLR）信号通路、Toll 样受体（TLR）信号通路、缺氧诱导因子-1（HIF-1）信号通路等发挥治疗肺炎的作用。
加味泻白散或加味泻白散联合阿奇霉素治疗肺炎的疗效较好，加味泻白散联合阿奇霉素可能通过 IL-17 信号通路等多种途径发挥治疗肺炎的作用。
